Taking into account the results of our study and the authors’ reports, the presence of CD34+CD38− may be considered a predictive marker in BCP-ALL, which could be used to individualize the treatment in children with this type of neoplasm (3). The gene discussed is CD34; the disease is acute lymphoblastic leukemia.